Antihypertension and colorectal cancer prevention: Getting two birds with one stone?

Journal of the National Cancer Institute

Volumn 106, Issue 2, 2014, Pages

  Song, Mingyang ^a   Giovannucci, Edward L ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

COLORECTAL TUMOR; FEMALE; HUMAN; HYPERTENSION; MALE; NOTE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICARCINOGENIC AGENTS; ANTIHYPERTENSIVE AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPERTENSION; MALE;

EID: 84893825565     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt438     Document Type: Editorial

References (17)

1. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352(9123):179-184.
2. Boudreau DM, Koehler E, Rulyak SJ, et al. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarker Prev 2008;17(11):3076-3080.
3. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92(9):2462-2470.
4. Azoulay L, Assimes TL, Yin H, et al. Long-term use of angiotensin receptor blockers and the risk of cancer. PloS One. 2012;7(12):e50893.
5. Huang CC, Chan WL, Chen YC, et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol. 2011;107(7):1028-1033.
6. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324, 168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82.
7. Barrios V, Escobar C. Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol. 2010;11(9):819-820; author reply 821-822.
8. Meredith PA, McInnes GT. Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol. 2010;11(9):819; author reply 821-822.
9. Makar GA, Holmes JH, Yang Y-X. Angiotensin converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst. 2014;106(2): XXX-XXX.
10. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615-625.
11. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10(11):745-759.
12. Kubota M, Shimizu M, Sakai H, et al. Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Biochem Biophys Res Comm. 2011;410(1):108-113.
13. Yasumaru M, Tsuji S, Tsujii M, et al. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulinlike growth factor I receptor pathway. Cancer Res. 2003;63(20):6726-6734.
14. International Society of Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Safety. 2008;17(2):200-208.
15. Van Der Knaap R, Siemes C, Coebergh JW, et al. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer. 2008;112(4):748-757.
16. Kedika R, Patel M, Pena Sahdala HN, et al. Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol. 2011;45(2):e12-e16.
17. Mansouri D, McMillan DC, Roxburgh CS, et al. The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme. Br J Cancer. 2013;109(1):249-256.